These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26105011)

  • 21. Generic drug approval: a US perspective.
    Nagori BP; Mathur V; Garg S
    Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
    Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
    AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
    Carrillo Norte JA; Postigo Mota S
    Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of generic agents in psychopharmacologic treatment.
    Kumet R; Gelenberg AJ
    Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The United States Food and Drugs Administration approves a generic enoxaparin.
    Ofosu FA
    Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When is a "generic" medication not really a generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 Feb; 48(2):13-6. PubMed ID: 20166651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
    Seoane-Vazquez E; Rodriguez-Monguio R; Hansen R
    Clin Drug Investig; 2016 Apr; 36(4):281-92. PubMed ID: 26818406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs.
    Hottinger M; Liang BA
    Am J Law Med; 2012; 38(4):667-89. PubMed ID: 23356099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generic drugs for the treatment of ocular conditions: changing the treatment landscape.
    Aref AA
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):551-3. PubMed ID: 24957466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
    Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
    Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
    JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic drug device combination products: Regulatory and scientific considerations.
    Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
    Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.
    van der Meersch A; Dechartres A; Ravaud P
    PLoS One; 2011; 6(8):e23611. PubMed ID: 21858184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Bioequivalence a Sufficient Measure of Equivalence?
    Holman A
    J Leg Med; 2019; 39(3):247-261. PubMed ID: 31626574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
    Kaffenberger BH; Bekaii-Saab T
    Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scientific considerations in the regulatory approval of generic (or biosimilar) version of enoxaparin sodium - A lifesaving carbohydrate polymer.
    Iqbal Z; Sadaf S
    Regul Toxicol Pharmacol; 2023 Sep; 143():105446. PubMed ID: 37532121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.